Olezarsen Fast Tracked for Familial Chylomicronemia Syndrome
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Evinacumab is a fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3.
The study included adults aged 40 to 75 years with no history of cardiovascular disease, an LDL-C of 70-189 mg/dL, and a 5-20% 10-year risk of ASCVD.
These recommendations apply only to individuals without a history of CVD and who are not already taking statins.
Evinacumab is a fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3
The decision was made based on data from a phase 2b study that evaluated vupanorsen in statin-treated patients with dyslipidemia.
The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD.
Study authors analyzed data from 10,541 hospitalized patients with active COVID-19 disease to evaluate the relationship between the use of statins and COVID-19 outcomes.
Cholestene, a dietary supplement marketed for cholesterol management, has been found to contain a hidden drug ingredient, according to the Food and Drug Administration. Based on laboratory analysis, the product, which is sold on various websites and in some retail stores, has been found to contain lovastatin, an HMG-CoA reductase inhibitor (statin). Consuming a supplement…
Small increases in the risk for statin-associated muscle symptoms were observed for patients on high-intensity therapy.